Cost-effective use of liposomal amphotericin B.
D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage / Q000191:economics*; D000935:Antifungal Agents / Q000008:administration & dosage / Q000191:economics*; D001228:Aspergillosis / Q000188:drug therapy; D002648:Child; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004739:England; D006801:Humans; D008081:Liposomes; D016031:Liver Transplantation; D008172:Lung Diseases, Fungal / Q000188:drug therapy; D008485:Medical Audit; D009181:Mycoses / Q000188:drug therapy / Q000517:prevention & control; D009503:Neutropenia / Q000150:complications; D016134:Organizational Policy; D011183:Postoperative Complications / Q000188:drug therapy / Q000517:prevention & control; D012852:Sinusitis / Q000188:drug therapy; D016896:Treatment Outcome
D000935:Antifungal Agents; D008081:Liposomes; D000666:Amphotericin B